Literature DB >> 23084550

Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction: the EXAMI study.

Flip J P Bernink, Leo Timmers, Michaela Diamant, Martijn Scholte, Aernout M Beek, Otto Kamp, Koen M J Marques, Robert N Denham, Weena J Y Chen, Pieter A Doevendans, Albert C van Rossum, Niels van Royen, Anton J G Horrevoets, Yolande Appelman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23084550     DOI： 10.1016/j.ijcard.2012.09.204

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  15 in total

Review 1.  Extra-pancreatic effects of incretin-based therapies.

Authors:  Baptist Gallwitz
Journal:  Endocrine       Date:  2014-03-07       Impact factor: 3.633

Review 2.  Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension.

Authors:  Nicholas E King; Evan Brittain
Journal:  Pulm Circ       Date:  2022-01-18       Impact factor: 2.886

3.  Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.

Authors:  Marat Fudim; Jennifer White; Neha J Pagidipati; Yuliya Lokhnygina; Julio Wainstein; Jan Murin; Nayyar Iqbal; Peter Öhman; Renato D Lopes; Barry Reicher; Rury R Holman; Adrian F Hernandez; Robert J Mentz
Journal:  Circulation       Date:  2019-09-23       Impact factor: 29.690

Review 4.  Effects of incretin-based therapy in patients with heart failure and myocardial infarction.

Authors:  Nasser Mikhail
Journal:  Endocrine       Date:  2014-02-04       Impact factor: 3.633

Review 5.  Novel adjunctive treatments of myocardial infarction.

Authors:  Michael Rahbek Schmidt; Kasper Pryds; Hans Erik Bøtker
Journal:  World J Cardiol       Date:  2014-06-26

6.  Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection.

Authors:  John R Ussher; Laurie L Baggio; Jonathan E Campbell; Erin E Mulvihill; Minsuk Kim; M Golam Kabir; Xiemin Cao; Benjamin M Baranek; Doris A Stoffers; Randy J Seeley; Daniel J Drucker
Journal:  Mol Metab       Date:  2014-05-09       Impact factor: 7.422

7.  DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome.

Authors:  Yochai Birnbaum; Dat Tran; Mandeep Bajaj; Yumei Ye
Journal:  Basic Res Cardiol       Date:  2019-08-06       Impact factor: 17.165

Review 8.  Ischaemic conditioning and reperfusion injury.

Authors:  Derek J Hausenloy; Derek M Yellon
Journal:  Nat Rev Cardiol       Date:  2016-02-04       Impact factor: 32.419

9.  Direct cardiovascular effects of glucagon like peptide-1.

Authors:  Asfandyar Sheikh
Journal:  Diabetol Metab Syndr       Date:  2013-08-29       Impact factor: 3.320

Review 10.  A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes.

Authors:  Stefano Genovese; Edoardo Mannucci; Antonio Ceriello
Journal:  Adv Ther       Date:  2017-07-03       Impact factor: 3.845
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.